3상모집 중
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
연구 개요
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Guérin (BCG) treated participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of high-risk non-muscle-invasive bladder cancer (HR-NMIBC).
- 스폰서
- 리드: 얀센(J&J)
- 적응증
- Non-Muscle Invasive Bladder Neoplasms
- 중재
- TAR-210, Mitomycin C, Gemcitabine
- 목표 등록
- 220명
- 시작일
- 2025-09-10
- 완료(예정)
- 2032-03-16
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.